Bydureon® BCise™ (exenatide extended-release) – New formulation approval
October 23, 2017 – AstraZeneca announced the FDA approval of Bydureon BCise (exenatide extended-release) injectable suspension as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Top